Regulation of Allergy with RNA interference

Critical Reviews in Immunology

Volumn 29, Issue 6, 2009, Pages 443-468

  Suzuki, Motohiko ^a,b   Zheng, Xiufen ^a   Zhang, Xusheng ^a   Zhang, Yuwei ^c   Ichim, Thomas E ^a   Min, Weiping ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b NAGOYA CITY UNIVERSITY   (Japan)

^c MediStem Laboratories Inc   (United States)

Author keywords

Allergy; Gene silencing; Immune modulation; Immunotherapy; RNA interference; SiRNA

Indexed keywords

AGN 211745; ANTISENSE OLIGONUCLEOTIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BEVASIRANIB; CD40 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR8; CORTICOSTEROID; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HISTAMINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; MOL 6131; MOMETASONE FUROATE; N (1 HYDROXY 2 NAPHTHOYL)ARGINYLPROLINAMIDE; PF 04523655; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STAT6 PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR NFAT3; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADRENAL CORTEX INSUFFICIENCY; AIRWAY OBSTRUCTION; ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ALLERGIC DISEASE; ALLERGIC RHINITIS; ATOPIC DERMATITIS; BONE DENSITY; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CATARACT; CLINICAL TRIAL; CONTACT ALLERGY; CORTICOSTEROID THERAPY; COUGHING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DYSPHONIA; EOSINOPHILIA; FEASIBILITY STUDY; FRACTURE; GLAUCOMA; GROWTH RETARDATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LEG LENGTH; LIVER FAILURE; LUNG EDEMA; NASAL PRURITUS; NONHUMAN; NOSE CONGESTION; OROPHARYNX CANDIDIASIS; OSTEOPOROSIS; PHARYNGITIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHINORRHEA; RNA INTERFERENCE; SIDE EFFECT; SKIN BRUISING; SKIN TOXICITY; SYMPTOM; TREATMENT INDICATION; VIRUS INFECTION;

EID: 76749112848     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevimmunol.v29.i6.10     Document Type: Review

References (185)

1. Poulsen LK, Hummelshoj L. Triggers of IgE class switching and allergy development. Ann Med. 2007; 39:440-456
2. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland J, Kann L, Lehoczky J, LeVine R, McEwan P, McKernan K, Meldrim J, Mesirov JP, Miranda C, Morris W, Naylor J, Raymond C, Rosetti M, Santos R, Sheridan A, Sougnez C, Stange-Thomann N, Stojanovic N, Subramanian A, Wyman D, Rogers J, Sulston J, Ainscough R, Beck S, Bentley D, Burton J, Clee C, Carter N, Coulson A, Deadman R, Deloukas P, Dunham A, Dunham I, Durbin R, French L, Grafham D, Gregory S, Hubbard T, Humphray S, Hunt A, Jones M, Lloyd C, McMurray A, Matthews L, Mercer S, Milne S, Mullikin JC, Mungall A, Plumb R, Ross M, Shownkeen R, Sims S, Waterston RH, Wilson RK, Hillier LW, McPherson JD, Marra MA, Mardis ER, Fulton LA, Chinwalla AT, Pepin KH, Gish WR, Chissoe SL, Wendl MC, Delehaunty KD, Miner TL, Delehaunty A, Kramer JB, Cook LL, Fulton RS, Johnson DL, Minx PJ, Clifton SW, Hawkins T, Branscomb E, Predki P, Richardson P, Wenning S, Slezak T, Doggett N, Cheng JF, Olsen A, Lucas S, Elkin C, Uberbacher E, Frazier M. Initial sequencing and analysis of the human genome. Nature. 2001;409:860-921.
3. Shirakawa T, Li A, Dubowitz M, Dekker JW, Shaw AE, Faux JA, Ra C, Cookson WO, Hopkin JM. Association between atopy and variants of the beta subunit of the high-affi nity immunoglobulin E receptor. Nat Genet. 1994;7:125-129
4. Liao H, Wang JH. Biomembrane-permeable and Ribonuclease-resistant siRNA with enhanced activity. Oligonucleotides. 2005;15:196-205.
5. Tong AW, Zhang YA, Nemunaitis J. Small interfering RNA for experimental cancer therapy. Curr Opin Mol Ther. 2005;7:114-124
6. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun. 2002;296:1000-1004
7. Thompson JD. Applications of antisense and siRNAs during preclinical drug development. Drug Discov Today. 2002;7:912-917
8. Senn C, Hangartner C, Moes S, Guerini D, Hofbauer KG. Central administration of small interfering RNAs in rats: a comparison with antisense oligonucleotides. Eur J Pharmacol. 2005;522:30-37
9. Shi HZ, Qin XJ. CD4CD25 regulatory T lymphocytes in allergy and asthma. Allergy. 2005;60:986-995
10. Wang YH, Liu YJ. The IL-17 cytokine family and their role in allergic inflammation. Curr Opin Immunol. 2008;20:697-702.
11. Hamelmann E, Gelfand EW. IL-5-induced airway eosinophilia\-the key to asthma? Immunol Rev. 2001; 179:182-191
12. Yamaguchi Y, Suda T, Suda J, Eguchi M, Miura Y, Harada N, Tominaga A, Takatsu K. Purifi ed inter-leukin 5 supports the terminal diff erentiation and proliferation of murine eosinophilic precursors. J Exp Med. 1988;167:43-56.
13. Jelinek DF. Regulation of B lymphocyte diff erentiation. Ann Allergy Asthma Immunol. 2000;84:375-85; quiz 385-387
14. Ammit AJ, Panettieri RA, Jr. Invited review: the circle of life: cell cycle regulation in airway smooth muscle. J Appl Physiol. 2001;91:1431-1437
15. Hamid Q, Tulic M. Immunobiology of asthma. Annu Rev Physiol. 2009;71:489-507.
16. Pelikan Z. Asthmatic response induced by nasal challenge with allergen. Int Arch Allergy Immunol. 2008; 148:330-338
17. Settipane RJ, Hagy GW, Settipane GA. Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc. 1994;15:21-25
18. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, Hamid Q, Kapp A, Leung DY, Lipozencic J, Luger TA, Muraro A, Novak N, Platts-Mills TA, Rosenwasser L, Scheynius A, Simons FE, Spergel J, Turjanmaa K, Wahn U, Weidinger S, Werfel T, Zuberbier T. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy. 2006;61:969-987 (Pubitemid 44024897)
19. Penagos M, Compalati E, Tarantini F, Baena-Cagnani CE, Passalacqua G, Canonica GW. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. Allergy. 2008;63:1280-1291
20. Busse WW, Pedersen S, Pauwels RA, Tan WC, Chen YZ, Lamm CJ, O'Byrne PM. The inhaled Steroid Treatment As Regular Therapy in early asthma (START) study 5-year follow-up: eff ectiveness of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol. 2008;121:1167-74.
21. Djukanovic R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR, Howarth PH, Holgate ST. Eff ect of an inhaled corticosteroid on airway infl am-mation and symptoms in asthma. Am Rev Respir Dis. 1992;145:669-674
22. Djukanovic R, Wilson JW, Lai CK, Holgate ST, Howarth PH. The safety aspects of fi beroptic bronchos-copy, bronchoalveolar lavage, and endobronchial biopsy in asthma. Am Rev Respir Dis. 1991;143:772-777
23. Adelroth E, Rosenhall L, Johansson SA, Linden M, Venge P. Infl ammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage. The eff ects of antiasthmatic treatment with budesonide or terbutaline. Am Rev Respir Dis. 1990;142:91-99
24. Holt PG, Thomas JA. Steroids inhibit uptake and/or processing but not presentation of antigen by airway dendritic cells. Immunology. 1997;91:145-150
25. Brokaw JJ, White GW, Baluk P, Anderson GP, Umemoto EY, McDonald DM. Glucocorticoid-induced apoptosis of dendritic cells in the rat tracheal mucosa. Am J Respir Cell Mol Biol. 1998;19:598-605.
26. Karagiannidis C, Akdis M, Holopainen P, Woolley NJ, Hense G, Ruckert B, Mantel PY, Menz G, Akdis CA, Blaser K, Schmidt-Weber CB. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol. 2004;114:1425-1433
27. Adcock IM, Barnes PJ. Molecular mechanisms of corticosteroid resistance. Chest. 2008;134:394-401.
28. Todd GR, Acerini CL, Buck JJ, Murphy NP, Ross-Russell R, Warner J T, McCance DR. Acute adrenal crisis in asthmatics treated with high-dose fl uticasone propionate. Eur Respir J. 2002;19:1207-1209
29. Dahl R. Systemic side eff ects of inhaled corticoster-oids in patients with asthma. Respir Med. 2006;100: 1307-1317
30. Lebedeva I, Stein CA. Antisense oligonucleotides: promise and reality. Annu Rev Pharmacol Toxicol. 2001;41:403-419
31. Gauvreau GM, Boulet LP, Cockcroft DW, Baatjes A, Cote J, Deschesnes F, Davis B, Strinich T, Howie K, Duong M, Watson RM, Renzi PM, O'Byrne PM. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med. 2008;177:952-8.
32. Crosby JR, Guha M, Tung D, Miller DA, Bender B, Condon TP, York-DeFalco C, Geary RS, Monia BP, Karras JG, Gregory SA. Inhaled CD86 antisense oligonucleotide suppresses pulmonary inflammation and airway hyper-responsiveness in allergic mice. J Pharmacol Exp Ther. 2007;321:938-946
33. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specifi c genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806-811 (Pubitemid 28099681)
34. Jorgensen RA, Cluster PD, English J, Que Q, Napoli CA. Chalcone synthase cosuppression phenotypes in petunia fl owers: comparison of sense vs. antisense constructs and single-copy vs. complex T-DNA sequences. Plant Mol Biol. 1996;31:957-973
35. Voinnet O. Induction and suppression of RNA silencing: insights from viral infections. Nat Rev Genet. 2005; 6:206-220
36. Ullu E, Djikeng A, Shi H, Tschudi C. RNA interference: advances and questions. Philos Trans R Soc Lond B Biol Sci. 2002;357:65-70.
37. Fire AZ. Gene silencing by double-stranded RNA (Nobel Lecture). Angew Chem Int Ed Engl. 2007;46: 6966-6984
38. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494-498
39. Proud CG. PKR: a new name and new roles. Trends Biochem Sci. 1995;20:241-246
40. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell. 2000:101:25-33.
41. Bartlett DW, Davis ME. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 2006;34:322-333
42. Saunders LR, Barber GN. The dsRNA binding protein family: critical roles, diverse cellular functions. FASEB J. 2003;17:961-983
43. Adah SA, Bayly SF, Cramer H, Silverman RH, Torrence PF. Chemistry and biochemistry of 2',5'-oligo-adenylate-based antisense strategy. Curr Med Chem. 2001;8:1189-1212
44. Williams BR. Signal integration via PKR. Sci STKE. 2001 Jul 3;2001(89):re2.
45. Schlee M, Hornung V, Hartmann G. siRNA and isRNA: two edges of one sword. Mol Ther. 2006;14: 463-470
46. Timmons L. The long and short of siRNAs. Mol Cell. 2002;10:435-437
47. Celotto AM, Lee JW, Graveley BR. Exon-specifi c RNA interference: a tool to determine the functional relevance of proteins encoded by alternatively spliced mRNAs. Methods Mol Biol. 2005;309:273-282
48. Grishok A, Tabara H, Mello CC. Genetic requirements for inheritance of RNAi in C. elegans. Science. 2000;287:2494-2497
49. Devroe E, Silver PA. Retrovirus-delivered siRNA. BMC Biotechnol. 2002;2:15.
50. Zheng X, Vladau C, Zhang X, Suzuki M, Ichim TE, Zhang ZX, Li M, Carrier E, Garcia B, Jevnikar AM, Min WP. A novel in vivo siRNA delivery system specifi cally targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood. 2009 Mar 19;113(12):2646-2654
51. Tuschl T. Expanding small RNA interference. Nat Biotechnol. 2002;20:446-448
52. Matsukura S, Jones PA, Takai D. Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res. 2003;31:e77.
53. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specifi c silencing in mammalian cells. Genes Dev. 2002;16:948-958
54. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296:550-553
55. McAnuff MA, Rettig GR, Rice KG. Potency of siRNA versus shRNA mediated knockdown in vivo. J Pharm Sci. 2007;96:2922-2930
56. Vlassov AV, Korba B, Farrar K, Mukerjee S, Seyhan AA, Ilves H, Kaspar RL, Leake D, Kazakov SA, Johnston BH. shRNAs targeting hepatitis C: eff ects of sequence and structural features, and comparision with siRNA. Oligonucleotides. 2007;17:223-236
57. Bose A, Guilherme A, Robida SI, Nicoloro SM, Zhou QL, Jiang ZY, Pomerleau DP, Czech MP. Glucose transporter recycling in response to insulin is facilitated by myosin Myo1c. Nature. 2002;420:821-824
58. Troussard AA, Mawji NM, Ong C, Mui A, St-Arnaud R, Dedhar S. Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation. J Biol Chem. 2003;278:22374-22378
59. Huang YZ, Zang M, Xiong WC, Luo Z, Mei L. Erbin suppresses the MAP kinase pathway. J Biol Chem. 2003;278:1108-1114
60. Foged C, Nielsen HM, Frokjaer S. Phospholipase A2 sensitive liposomes for delivery of small interfering RNA (siRNA). J Liposome Res. 2007;17:191-196
61. Torchilin VP. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng. 2006;8:343-375
62. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Röhl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher HP. Therapeutic silencing of an endogenous gene by systemic administration of modifi ed siRNAs. Nature. 2004;432:173-178
63. Kim SH, Jeong JH, Kim TI, Kim SW, Bull DA. VEGF siRNA delivery system using arginine-grafted bioreducible poly(disulfi de amine). Mol Pharm. 2009 May-Jun;6(3):718-726
64. Czauderna F, Fechtner M, Dames S, Aygün H, Klippel A, Pronk GJ, Giese K, Kaufmann J. Structural variations and stabilising modifi cations of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 2003; 31:2705-2716
65. Morris KV, Rossi JJ. Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther. 2006;13: 553-558
66. Grimm D, Kay MA. Therapeutic short hairpin RNA expression in the liver: viral targets and vectors. Gene Ther. 2006;13:563-575
67. Zhang X, Shan P, Jiang D, Noble PW, Abraham NG, Kappas A, Lee PJ. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J Biol Chem. 2004; 279:10677-10684
68. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med. 2005;11:50-55
69. Massaro D, Massaro GD, Clerch LB. Noninvasive delivery of small inhibitory RNA and other reagents to pulmonary alveoli in mice. Am J Physiol Lung Cell Mol Physiol. 2004;287:L1066-70.
70. Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, Johnson JM, Lim L, Karpilow J, Nichols K, Marshall W, Khvorova A, Linsley PS. Position-specifi c chemical modifi cation of siRNAs reduces "off- target" transcript silencing. RNA. 2006;12:1197-1205
71. Ma Z, Li J, He F, Wilson A, Pitt B, Li S. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem Biophys Res Commun. 2005;330:755-759
72. Sioud M, Furset G, Cekaite L. Suppression of immuno stimulatory siRNA-driven innate immune activation by 2'-modifi ed RNAs. Biochem Biophys Res Commun. 2007;361:122-126
73. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006;441:537-541
74. Kubo T, Zhelev Z, Ohba H, Bakalova R. Chemically modifi ed symmetric and asymmetric duplex RNAs: an enhanced stability to nuclease degradation and gene silencing eff ect. Biochem Biophys Res Commun. 2008;365:54-61.
75. Kraynack BA, Baker BF. Small interfering RNAs containing full 2'-O-methylribonucleotide-modifi ed sense strands display Argonaute2/eIF2C2- dependent activity. RNA. 2006;12:163-176
76. Choung S, Kim YJ, Kim S, Park HO, Choi YC. Chemical modifi cation of siRNAs to improve serum stability without loss of effi cacy. Biochem Biophys Res Commun. 2006;342:919-927
77. Allerson CR, Sioufi N, Jarres R, Prakash T P, Naik N, Berdeja A, Wanders L, Griffey RH, Swayze EE, Bhat B. Fully 2'-modifi ed oligonucleotide duplexes with improved in vitro potency and stability compared to unmodifi ed small interfering RNA. J Med Chem. 2005;48:901-904
78. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C, Bowman K, Shaff er CS, Jeff s LB, Judge A, MacLachlan I, Polisky B. Potent and persistent in vivo anti-HBV activity of chemically modifi ed siRNAs. Nat Biotechnol. 2005; 23:1002-1007
79. Scacheri PC, Rozenblatt-Rosen O, Caplen NJ, Wolfsberg TG, Umayam L, Lee JC, Hughes CM, Shanmugam KS, Bhattacharjee A, Meyerson M, Collins FS. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci USA. 2004;101:1892-1897
80. Bramsen JB, Laursen MB, Damgaard CK, Lena SW, Babu BR, Wengel J, Kjems J. Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res. 2007;35:5886-5897
81. Chen PY, Weinmann L, Gaidatzis D, Pei Y, Zavolan M, Tuschl T, Meister G. Strand-specifi c 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specifi city. RNA. 2008; 14:263-274
82. Ui-Tei K, Naito Y, Zenno S, Nishi K, Yamato K, Takahashi F, Juni A, Saigo K. Functional dissection of siRNA sequence by systematic DNA substitution: modifi ed siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with signifi cantly reduced off-target eff ect. Nucleic Acids Res. 2008;36:2136-2151
83. Clark PR, Pober JS, Kluger MS. Knockdown of TNFR1 by the sense strand of an ICAM-1 siRNA: dissection of an off-target effect. Nucleic Acids Res. 2008;36:1081-1097
84. Lorenz C, Hadwiger P, John M, Vornlocher HP, Unverzagt C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett. 2004;14:4975-4977
85. Nishina K, Unno T, Uno Y, Kubodera T, Kanouchi T, Mizusawa H, Yokota T. Effi cient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol Ther. 2008;16:734-740
86. Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, Rajeev KG, Nakayama T, Charrise K, Ndungo EM, Zimmermann T, Koteliansky V, Manoharan M, Stoff el M. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol. 2007;25:1149-1157
87. Muratovska A, Eccles MR. Conjugate for effi cient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett. 2004;558:63-68
88. de Fougerolles A, Vornlocher H P, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007;6:443-453
89. Tompkins SM, Lo CY, Tumpey TM, Epstein SL. Protection against lethal infl uenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci USA. 2004;101:8682-8686
90. Li BJ, Tang Q, Cheng D, Qin C, Xie FY, Wei Q, Xu J, Liu Y, Zheng BJ, Woodle MC, Zhong N, Lu PY. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med. 2005;11:944-951
91. Kumar P, Lee SK, Shankar P, Manjunath N. A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PLoS Med. 2006;3:e96.
92. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F. siRNA targeting of the viral E6 oncogene effi ciently kills human papillomavirus-positive cancer cells. Oncogene. 2003; 22:5938-5945
93. Randall G, Grakoui A, Rice CM. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc Natl Acad Sci USA. 2003;100:235-240
94. Giladi H, Ketzinel-Gilad M, Rivkin L, Felig Y, Nussbaum O, Galun E. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther. 2003;8:769-776
95. Rossi JJ, June CH, Kohn DB. Genetic therapies against HIV. Nat Biotechnol. 2007;25:1444-1454
96. Pal A, Ahmad A, Khan S, Sakabe I, Zhang C, Kasid UN, Ahmad I. Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int J Oncol. 2005;26:1087-1091
97. Yano J, Hirabayashi K, Nakagawa S, Yamaguchi T, Nogawa M, Kashimori I, Naito H, Kitagawa H, Ishiyama K, Ohgi T, Irimura T. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res. 2004;10: 7721-7726
98. Shen HL, Xu W, Wu ZY, Zhou LL, Qin RJ, Tang HR. Vector-based RNAi approach to isoform-specifi c downregulation of vascular endothelial growth factor (VEGF)165 expression in human leukemia cells. Leuk Res. 2007;31:515-521
99. Hua J, Mutch DG, Herzog TJ. Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line. Gynecol Oncol. 2005;98:31-38
100. Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, Bennett J, Tolentino MJ. Small interfering RNA (siRNA) targeting VEGF eff ectively inhibits ocular neovascularization in a mouse model. Mol Vis. 2003;9:210-216
101. Tolentino MJ, Brucker AJ, Fosnot J, Ying GS, Wu IH, Malik G, Wan S, Reich SJ. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascu-larization. Retina. 2004;24:132-138 (Pubitemid 38240851)
102. Shen J, Samul R, Silva RL, Akiyama H, Liu H, Saishin Y, Hackett SF, Zinnen S, Kossen K, Fosnaugh K, Vargeese C, Gomez A, Bouhana K, Aitchison R, Pavco P, Campochiaro PA. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther. 2006;13:225-234
103. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, Albuquerque RJ, Yamasaki S, Itaya M, Pan Y, Appukuttan B, Gibbs D, Yang Z, Karikó K, Ambati BK, Wilgus TA, DiPietro LA, Sakurai E, Zhang K, Smith JR, Taylor EW, Ambati J. Sequence-and target-independent angiogenesis suppres sion by siRNA via TLR3. Nature. 2008;452:591-597
104. Inoue T, Sugimoto M, Sakurai T, Saito R, Futaki N, Hashimoto Y, Honma Y, Arai I, Nakaike S. Modulation of scratching behavior by silencing an endogenous cyclooxygenase-1 gene in the skin through the administration of siRNA. J Gene Med. 2007;9:994-1001.
105. Heijink IH, Kies PM, Kauff man HF, Postma DS, van Oosterhout AJ, Vellenga E. Down-regulation of E-cadherin in human bronchial epithelial cells leads to epidermal growth factor receptor-dependent T 2 cell-promoting activity. J Immunol. 2007;178:7678-7685
106. Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, Kohler G. Disruption of the murine IL-4 gene blocks T 2 cytokine responses. Nature. 1993;362:245-248
107. Benbernou N, Matsiota-Bernard P, Guenounou M. Antisense oligonucleotides to interleukin-4 regulate IgE and IgG2a production by spleen cells from Nippostrongylus brasiliensis-infected rats. Eur J Immunol. 1993;23:659-663
108. Molet S, Ramos-Barbon D, Martin JG, Hamid Q. Adoptively transferred late allergic response is inhibited by IL-4, but not IL-5, antisense oligonucleotide. J Allergy Clin Immunol. 1999;104:205-214
109. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG. Interleukin 5 defficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med. 1996;183:195-201.
110. Huang HY, Lee CC, Chiang BL. Small interfering RNA against interleukin-5 decreases airway eosino-philia and hyper-responsiveness. Gene Ther. 2008; 15:660-667
111. Karras JG, McGraw K, McKay RA, Cooper SR, Lerner D, Lu T, Walker C, Dean NM, Monia BP. Inhibition of antigen-induced eosinophilia and late phase airway hyperresponsiveness by an IL-5 antisense oligonucleotide in mouse models of asthma. J Immunol. 2000;164:5409-5415
112. Grünig G, Warnock M, Wakil AE, Venkayya R, sBrombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry DB. Requirement for IL-13 independently of IL-4 in experimental asthma. Science. 1998;282:2261-2263
113. Wills-Karp M, Luyimbazi J, Xu X, Schofi eld B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science. 1998;282:2258-2261
114. Kim HM, Lee YM. Role of TGF-beta 1 on the IgE-dependent anaphylaxis reaction. J Immunol. 1999;162: 4960-4965
115. Kips JC, Tavernier JH, Joos GF, Peleman RA, Pauwels RA. The potential role of tumour necrosis factor alpha in asthma. Clin Exp Allergy. 1993;23:247-250
116. Ouyang W, Löhning M, Gao Z, Assenmacher M, Ranganath S, Radbruch A, Murphy KM. Stat6-independent GATA-3 autoactivation directs IL-4-independent T 2 development and commitment. Immunity. 2000;12:27-37.
117. Hill S, Herlaar E, Le Cardinal A, van Heeke G, Nicklin P. Homologous human and murine antisense oligonucleotides targeting stat6. Functional eff ects on germline cepsilon transcript. Am J Respir Cell Mol Biol. 1999;21:728-737
118. Rippmann JF, Schnapp A, Weith A, Hobbie S. Gene silencing with STAT6 specifi c siRNAs blocks eotaxin release in IL-4/TNFalpha stimulated human epithelial cells. FEBS Lett. 2005;579:173-178
119. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and suffi cient for T 2 cytokine gene expression in CD4 T cells. Cell. 1997;89:587-596
120. Finotto S, De Sanctis GT, Lehr HA, Herz U, Buerke M, Schipp M, Bartsch B, Atreya R, Schmitt E, Galle PR, Renz H, Neurath MF. Treatment of allergic airway infl ammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med. 2001;193:1247-1260
121. Choi IW, Kim DK, Ko HM, Lee HK. Administration of antisense phosphorothioate oligonucleotide to the p65 subunit of NF-kappaB inhibits established asthmatic reaction in mice. Int Immunopharmacol. 2004;4:1817-1828
122. Kim JI, Ho IC, Grusby MJ, Glimcher LH. The transcription factor c-Maf controls the production of inter-leukin-4 but not other T 2 cytokines. Immunity. 1999; 10:745-751
123. Kimura M, Koseki Y, Yamashita M, Watanabe N, Shimizu C, Katsumoto T, Kitamura T, Taniguchi M, Koseki H, Nakayama T. Regulation of T 2 cell differentiation by mel-18, a mammalian polycomb group gene. Immunity. 2001;15:275-287
124. Adcock IM, Chung KF, Caramori G, Ito K. Kinase inhibitors and airway infl ammation. Eur J Pharmacol. 2006;533:118-132
125. Duan W, Chan JH, McKay K, Crosby JR, Choo HH, Leung BP, Karras JG, Wong WS. Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med. 2005;171:571-578
126. Lee JH, Ko NY, Kim NW, Mun SH, Kim JW, Her E, Kim BK, Seo DW, Chang HW, Moon TC, Han JW, Kim YM, Choi WS. Meliae cortex extract exhibits anti-allergic activity through the inhibition of Syk kinase in mast cells. Toxicol Appl Pharmacol. 2007;220:227-234
127. Stenton GR, Ulanova M, Déry RE, Merani S, Kim MK, Gilchrist M, Puttagunta L, Musat-Marcu S, James D, Schreiber AD, Befus AD. Inhibition of allergic infl ammation in the airways using aerosolized antisense to Syk kinase. J Immunol. 2002;169:1028-1036
128. Pazdrak K, Olszewska-Pazdrak B, Staff ord S, Garofalo R P, Alam R. Lyn, Jak2, and Raf-1 kinases are critical for the antiapoptotic eff ect of interleukin 5, whereas only Raf-1 kinase is essential for eosinophil activation and degranulation. J Exp Med. 1998;188:421-429
129. Stafford S, Lowell C, Sur S, Alam R. Lyn tyrosine kinase is important for IL-5-stimulated eosinophil diff erentiation. J Immunol. 2002;168:1978-1983
130. Lach-Trifi lieff E, McKay RA, Monia BP, Karras JG, Walker C. In vitro and in vivo inhibition of interleukin (IL)-5-mediated eosinopoiesis by murine IL-5Ralpha antisense oligonucleotide. Am J Respir Cell Mol Biol. 2001;24:116-122
131. Kim HM, Kim KS, Lee EH. Specifi c inhibition of immunoglobulin E-mediated allergic reaction using antisense Fc epsilon RI alpha oligodeoxynucleotides. Immunology. 1998;93:589-594
132. Lukacs NW, Berlin A, Schols D, Skerlj R T, Bridger GJ. AMD3100, a CxCR4 antagonist, attenuates allergic lung infl ammation and airway hyperreactivity. Am J Pathol. 2002;160:1353-1360
133. Campbell EM, Charo IF, Kunkel SL, Strieter RM, Boring L, Gosling J, Lukacs NW. Monocyte chemoat-tractant protein-1 mediates cockroach allergen-induced bronchial hyperreactivity in normal but not CCR2-/-mice: the role of mast cells. J Immunol. 1999;163:2160-2167
134. Erin EM, Williams TJ, Barnes PJ, Hansel T T. Eotaxin receptor (CCR3) antagonism in asthma and allergic disease. Curr Drug Targets Infl amm Allergy. 2002;1:201-214
135. Nyce J. Respirable antisense oligonucleotides: a new, third drug class targeting respiratory disease. Curr Opin Allergy Clin Immunol. 2002;2:533-536
136. Allam M, Renzi PM. Inhibition of GM-CSF/IL-3/ IL-5 signaling by antisense oligodeoxynucleotides targeting the common beta chain of their receptors. Antisense Nucleic Acid Drug Dev. 2001;11:289-300.
137. Allakhverdi Z, Allam M, Renzi PM. Inhibition of antigen-induced eosinophilia and airway hyperrespon-siveness by antisense oligonucleotides directed against the common beta chain of IL-3, IL-5, GM-CSF receptors in a rat model of allergic asthma. Am J Respir Crit Care Med. 2002;165:1015-1021
138. Wegner CD, Gundel RH, Reilly P, Haynes N, Letts LG, Rothlein R. Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. Science. 1990;247:456-459
139. Hanai K, Kurokawa T, Minakuchi Y, Maeda M, Nagahara S, Miyata T, Ochiya T, Sano A. Potential of atelocollagen-mediated systemic antisense therapeutics for infl ammatory disease. Hum Gene Ther. 2004; 15:263-272
140. Chhabra A, Chakraborty NG, Mukherji B. Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-1 27-35. Clin Immunol. 2008;126:251-259
141. Hoey T, Grusby MJ. STATs as mediators of cytokine-induced responses. Adv Immunol. 1999;71:145-162
142. Kaplan MH, Sun YL, Hoey T, Grusby MJ. Impaired IL-12 responses and enhanced development of T 2 cells in Stat4-defi cient mice. Nature. 1996;382:174-177
143. T ierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT, Sangster MY, Vignali DA, Doherty PC, Grosveld GC, Ihle JN. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature. 1996 Jul 11;382(6587):171-174
144. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for development of T 2 cells. Immunity. 1996;4:313-319
145. Kozma N, Halasz M, Polgar B, Poehlmann TG, Markert UR, Palkovics T, Keszei M, Par G, Kiss K, Szeberenyi J, Grama L, Szekeres-Bartho J. Progesterone-induced blocking factor activates STAT6 via binding to a novel IL-4 receptor. J Immunol. 2006;176:819-826
146. Zhu J, Min B, Hu-Li J, Watson CJ, Grinberg A, Wang Q, Killeen N, Urban JF Jr, Guo L, Paul WE. Conditional deletion of Gata3 shows its essential function in T(H)1-T(H)2 responses. Nat Immunol. 2004; 5:1157-1165
147. Ferber IA, Lee HJ, Zonin F, Heath V, Mui A, Arai N, O'Garra A. GATA-3 signifi cantly downregulates IFN-gamma production from developing T 1 cells in addition to inducing IL-4 and IL-5 levels. Clin Immunol. 1999;91:134-144
148. Lee HJ, O'Garra A, Arai K, Arai N. Characterization of cis-regulatory elements and nuclear factors conferring T 2-specifi c expression of the IL-5 gene: a role for a GATA-binding protein. J Immunol. 1998;160: 2343-2352
149. Maneechotesuwan K, Xin Y, Ito K, Jazrawi E, Lee KY, Usmani OS, Barnes PJ, Adcock IM. Regulation of T 2 cytokine genes by p38 MAPK-mediated phosphoryla-tion of GATA-3. J Immunol. 2007;178:2491-2498
150. Zhao X, Zheng B, Huang Y, Yang D, Katzman S, Chang C, Fowell D, Zeng WP. Interaction between GATA-3 and the transcriptional coregulator Pias1 is important for the regulation of T 2 immune responses. J Immunol. 2007;179:8297-8304
151. Nigo YI, Yamashita M, Hirahara K, Shinnakasu R, Inami M, Kimura M, Hasegawa A, Kohno Y, Nakayama T. Regulation of allergic airway infl amma-tion through Toll-like receptor 4-mediated modifi cation of mast cell function. Proc Natl Acad Sci USA. 2006;103:2286-2291
152. Klein M, Klein-Hessling S, Palmetshofer A, Serfl ing E, Tertilt C, Bopp T, Heib V, Becker M, Taube C, Schild H, Schmitt E, Stassen M. Specifi c and redundant roles for NFAT transcription factors in the expression of mast cell-derived cytokines. J Immunol. 2006;177:6667-6674
153. Lin KW, Park J, Crews AL, Li Y, Adler KB. Protease-activated receptor-2 (PAR-2) is a weak enhancer of mucin secretion by human bronchial epithelial cells in vitro. Int J Biochem Cell Biol. 2008;40:1379-1388
154. Trian T, Girodet PO, Ousova O, Marthan R, Tunon-de-Lara JM, Berger P. RNA interference decreases PAR-2 expression and function in human airway smooth muscle cells. Am J Respir Cell Mol Biol. 2006;34:49-55.
155. Clark JM, Abraham WM, Fishman CE, Forteza R, Ahmed A, Cortes A, Warne RL, Moore WR, Tanaka RD. Tryptase inhibitors block allergen-induced airway and infl ammatory responses in allergic sheep. Am J Respir Crit Care Med. 1995;152:2076-2083
156. Oh SW, Pae CI, Lee DK, Jones F, Chiang GK, Kim HO, Moon SH, Cao B, Ogbu C, Jeong KW, Kozu G, Nakanishi H, Kahn M, Chi EY, Henderson WR Jr. Tryptase inhibition blocks airway infl ammation in a mouse asthma model. J Immunol. 2002;168:1992-2000.
157. Hata D, Kawakami Y, Inagaki N, Lantz CS, Kitamura T, Khan WN, Maeda-Yamamoto M, Miura T, Han W, Hartman SE, Yao L, Nagai H, Goldfeld AE, Alt FW, Galli SJ, Witte ON, Kawakami T. Involvement of Bruton's tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production. J Exp Med. 1998;187:1235-1247
158. Heinonen JE, Smith CI, Nore BF. Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA). FEBS Lett. 2002;527:274-278
159. Platz J, Pinkenburg O, Beisswenger C, Puchner A, Damm T, Bals R. Application of small interfering RNA (siRNA) for modulation of airway epithelial gene expression. Oligonucleotides. 2005;15:132-138
160. Chen SX, Huang FY, Tan GH, Wang CC, Huang YH, Wang H, Zhou SL, Chen F, Lin YY, Liu JB. RNA interference against interleukin-5 attenuates airway infl ammation and hyperresponsiveness in an asthma model. J Zhejiang Univ Sci B. 2009;10:22-28
161. Ritprajak P, Hashiguchi M, Azuma M. Topical application of cream-emulsifi ed CD86 siRNA ameliorates allergic skin disease by targeting cutaneous dendritic cells. Mol Ther. 2008;16:1323-1330
162. Pushparaj PN, Manikandan J, Tay HK, H'ng SC, Kumar SD, Pfeilschifter J, Huwiler A, Melendez AJ. Sphingosine kinase 1 is pivotal for Fc epsilon RI-mediated mast cell signaling and functional responses in vitro and in vivo. J Immunol. 2009;183:221-227
163. Zhi L, Leung BP, Melendez AJ. Sphingosine kinase 1 regulates pro-infl ammatory responses triggered by TNFalpha in primary human monocytes. J Cell Physiol. 2006;208:109-115
164. Lai WQ, Goh HH, Bao Z, Wong WS, Melendez AJ, Leung B P. The role of sphingosine kinase in a murine model of allergic asthma. J Immunol. 2008;180:4323-4329
165. Ohbayashi H, Suito H, Takagi K. Compared eff ects of natriuretic peptides on ovalbumin-induced asthmatic model. Eur J Pharmacol. 1998;346:55-64.
166. Wang X, Xu W, Mohapatra S, Kong X, Li X, Lockey RF, Mohapatra SS. Prevention of airway infl ammation with topical cream containing imiquimod and small interfering RNA for natriuretic peptide receptor. Genet Vaccines Ther. 2008;6:7.
167. Lee CC, Huang HY, Chiang BL. Lentiviral-mediated GATA-3 RNAi decreases allergic airway inflammation and hyperresponsiveness. Mol Ther. 2008;16:60-65
168. Darcan-Nicolaisen Y, Meinicke H, Fels G, Hegend O, Haberland A, Kühl A, Loddenkemper C, Witzenrath M, Kube S, Henke W, Hamelmann E. Small interfering RNA against transcription factor STAT6 inhibits allergic airway infl ammation and hyperreactivity in mice. J Immunol. 2009;182:7501-7508
169. Peng X, Kasran A, Warmerdam PA, de Boer M, Ceuppens JL. Accessory signaling by CD40 for T cell activation: induction of T 1 and T 2 cytokines and synergy with interleukin-12 for interferon-gamma production. Eur J Immunol. 1996;26:1621-1627
170. Suzuki M, Zheng X, Zhang X, Li M, Vladau C, Ichim TE, Sun H, Min LR, Garcia B, Min WP. Novel vaccination for allergy through gene silencing of CD40 using small interfering RNA. J Immunol. 2008;180:8461-8469
171. Suzuki M, Zheng X, Zhang X, Ichim TE, Sun H, Kubo N, Beduhn M, Shunnar A, Garcia B, Min WP. Inhibition of allergic responses by CD40 gene silencing. Allergy. 2009 Mar;64(3):387-397
172. Xu G, Mou Z, Jiang H, Cheng L, Shi J, Xu R, Oh Y, Li H. A possible role of CD4+CD25+ T cells as well as transcription factor Foxp3 in the dysregulation of allergic rhinitis. Laryngoscope. 2007;117:876-880
173. Pluvinet R, Pétriz J, Torras J, Herrero-Fresneda I, Cruzado JM, Grinyó JM, Aran JM. RNAi-mediated silencing of CD40 prevents leukocyte adhesion on CD154-activated endothelial cells. Blood. 2004;104: 3642-3646
174. Inaba K, Metlay JP, Crowley MT, Witmer-Pack M, Steinman RM. Dendritic cells as antigen presenting cells in vivo. Int Rev Immunol. 1990;6:197-206.
175. Liang X, Lu L, Chen Z, Vickers T, Zhang H, Fung JJ, Qian S. Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival. Transplantation. 2003;76:721-729 (Pubitemid 37072011)
176. Henry E, Desmet CJ, Garzé V, Fiévez L, Bedoret D, Heirman C, Faisca P, Jaspar FJ, Gosset P, Jacquet AP, Desmecht D, T ielemans K, Lekeux P, Moser M, Bureau F. Dendritic cells genetically engineered to express IL-10 induce long-lasting antigen-specifi c tolerance in experimental asthma. J Immunol. 2008;181:7230-7242
177. Li M, Zhang X, Zheng X, Lian D, Zhang ZX, Ge W, Yang J, Vladau C, Suzuki M, Chen D, Zhong R, Garcia B, Jevnikar AM, Min WP. Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference. J Immunol. 2007; 178:5480-5487
178. Cottrez F, Hurst SD, Coff man RL, Groux H. Thregulatory cells 1 inhibit a T 2-specifi c response in vivo. J Immunol. 2000;165:4848-4853
179. Kearley J, Robinson DS, Lloyd CM. CD4+CD25+ regulatory T cells reverse established allergic airway infl ammation and prevent airway remodeling. J Allergy Clin Immunol. 2008;122:617-624
180. Min WP, Zhou D, Ichim TE, Strejan GH, Xia X, Yang J, Huang X, Garcia B, White D, Dutartre P, Jevnikar AM, Zhong R. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol. 2003;170:1304-1312
181. Zhang X, Li M, Lian D, Zheng X, Zhang ZX, Ichim TE, Xia X, Huang X, Vladau C, Suzuki M, Garcia B, Jevnikar AM, Min WP. Generation of therapeutic dendritic cells and regulatory T cells for preventing allogeneic cardiac graft rejection. Clin Immunol. 2008; 127:313-321
182. Enk AH. DCs and cytokines cooperate for the induction of tregs. Ernst Schering Res Found Workshop. 2006;97-106.
183. Corinti S, Albanesi C, la Sala A, Pastore S, Girolomoni G. Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol. 2001;166:4312-4318
184. Selenko-Gebauer N, Majdic O, Szekeres A, Höfl er G, Guthann E, Korthäuer U, Zlabinger G, Steinberger P, Pickl WF, Stockinger H, Knapp W, Stöckl J. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol. 2003;170:3637-3644
185. Ureta G, Osorio F, Morales J, Rosemblatt M, Bono MR, Fierro JA. Generation of dendritic cells with regulatory properties. Transplant Proc. 2007;39:633-637